Focusing on GLP-1 receptors now has the FDA’s blessing as a option to deal with the fatty liver illness known as MASH with Novo Nordisk’s weekly injectable drug Wegovy changing into the second authorised therapy for this prevalent metabolic dysfunction.
In MASH, brief for metabolic dysfunction-associated steatohepatitis, the buildup of fats within the liver results in irritation and scarring of the organ, which is known as fibrosis. In accordance with the FDA, an estimated 14.9 million adults within the U.S. have MASH and its prevalence is rising. The late Friday regulatory determination for Wegovy covers the therapy of adults whose MASH has led to moderate-to-severe fibrosis. These sufferers should not have MASH that has progressed to liver cirrhosis, probably the most superior stage of the illness. Like its earlier approval in weight problems, Wegovy’s MASH approval covers use of the drug alongside weight-reduction plan and train.
The energetic ingredient in Wegovy is semaglutide, a peptide engineered to focus on and activate GLP-1 receptors within the intestine. This strategy promotes satiety and delays gastric emptying, serving to sufferers really feel full so that they eat much less. This mechanism of motion supported the drug’s preliminary approval in weight problems. The best way Wegovy works to deal with MASH shouldn’t be absolutely understood, however decreasing physique fats is assumed to contribute to liver profit. Approval of the two.4 mg dose of Wegovy in MASH relies on interim outcomes from a placebo-controlled Part 3 medical trial evaluating 1,197 sufferers with moderate-to-severe MASH. At week 72, leads to 800 trial contributors confirmed 63% achieved MASH decision and no worsening of fibrosis, a purpose achieved by 34% of these within the placebo arm.
The regulatory determination for Wegovy in MASH is an accelerated approval based mostly on the interim outcomes at 72 weeks. That profit should be confirmed by the continued Part 3 trial. Investigators will look to see whether or not the irritation and scarring enhancements noticed on the interim 72-week mark translate into decreases in demise, liver transplants, and different liver-related occasions measured at 240 weeks.
Wegovy was authorised for treating weight problems in 2021. Final 12 months, the drug expanded its U.S. and European approvals to incorporate decreasing the danger of heart problems, coronary heart assault, and stroke in adults with weight problems or obese. Throughout all of Wegovy’s authorised makes use of, Novo Nordisk reported greater than 36.8 billion Danish krone (about $5.7 billion) in gross sales within the first half of this 12 months.
“The FDA’s conditional approval of Wegovy for the therapy of adults with noncirrhotic MASH marks a really pivotal milestone and a major step ahead for the MASH group and people searching for new choices,” Dave Moore, Novo Nordisk’s government vice chairman of U.S. Operations mentioned in a ready assertion.
With its newest FDA approval, Wegovy will now compete in opposition to Rezdiffra, the Madrigal Prescription drugs drug whose accelerated approval final 12 months made it the primary MASH drug. The small molecule, formulated as a once-daily capsule, works by concentrating on and activating a receptor within the liver known as thyroid hormone receptor beta (THR-beta), mediating metabolic exercise within the organ. In Madrigal’s report of second quarter 2025 monetary outcomes, the corporate mentioned Rezdiffra accounted for greater than $350 million in income within the first half of this 12 months.
In a be aware despatched to traders Saturday, Leerink Companions analyst Thomas Smith mentioned that whereas his agency believes medicine like Wegovy will discover use treating some features of MASH, the agency expects drug combos spanning a number of drug courses will develop into the usual of take care of this illness. Based mostly on discussions with clinicians, Smith mentioned Leerink expects incretin mimetics, together with Wegovy, are more likely to be most well-liked for brand new MASH sufferers who’ve metabolic traits of the illness, similar to weight problems and heart problems, and who aren’t presently receiving treatment to handle these comorbidities.
Leerink nonetheless tasks sturdy market uptake for Rezdiffra, with the Madrigal drug being most well-liked for sufferers who’re already taking a GLP-1 agonist. The agency notes that about 25% of sufferers taking Rezdiffra are additionally presently taking a GLP-1 drug and half of sufferers have tried a GLP-1 drug previously.
One other issue is the rising use of Eli Lilly’s tirzepatide, the GLP-1- and GIP receptor-targeting peptide marketed as Mounjaro for sort 2 diabetes and as Zepbound for weight administration. Smith mentioned it’s unlikely a doctor will change a affected person already taking one among these Lilly medicine to Novo Nordisk’s product merely due to its MASH approval. For these sufferers, Rezdiffra can be the drug of alternative added on prime of tirzepatide. That mentioned, Lilly is getting ready to advance to Part 3 checks in MASH with tirzepatide and retatrutide, a peptide engineered to go after three targets.
For a few years, MASH (previously often called non-alcoholic steatohepatitis, or NASH) was a troublesome indication for drug builders. Genfit and Intercept Prescription drugs are among the many biotechs that encountered medical trial and regulatory setbacks within the metabolic illness. However Leerink’s Smith says the FDA nod for Wegovy in MASH, with a label per the drug’s medical trial expertise, bolsters confidence within the accelerated approval pathway for this indication. Leerink sees the most recent Wegovy approval having constructive readthrough to different medicine in late-stage improvement for MASH.
Akero Therapeutics is presently in Part 3 testing with efruxifermin, a fusion protein engineered to imitate FGF21, a protein within the physique known as that regulates vitality expenditure and fats metabolization. The biotech has already reported Part 2 outcomes exhibiting this once-weekly injection met trial objectives exhibiting enchancment on measures of MASH at 96 weeks. Extra detailed outcomes had been printed final week within the journal The Lancet. 89bio can also be in Part 3 testing with pegozafermin, an engineered model of FGF21. Sagimet Biosciences takes a unique strategy with denifanstat, an oral small molecule inhibitor of fatty acid synthase (FASN).
“Shifting ahead, we’re inspired with FDA’s label consistency, well timed nature of accelerated approvals, and more and more progressive views on noninvasive checks (NITs) —all of that are remodeling the perceived issue of the regulatory path, in addition to the medical and industrial MASH panorama,” Smith mentioned.
Picture: Michael Siluk/UCG/Common Photographs Group, through Getty Photographs